We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-0.93%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.52B
AUM Growth
-$149M
(-8.9%)
Cap. Flow
-$56.4M
Cap. Flow
% of AUM
-3.71%
Top 10 Holdings %
Top 10 Hldgs %
43.87%
Holding
86
New
7
Increased
23
Reduced
23
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$25.6M |
| 2 |
PHLT
Performant Healthcare Inc
PHLT
|
+$19.6M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$19.2M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$15.7M |
| 5 |
MaxCyte
MXCT
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$38.6M |
| 2 |
Glaukos
GKOS
|
+$34.7M |
| 3 |
Prothena Corp
PRTA
|
+$29.7M |
| 4 |
Halozyme
HALO
|
+$23.9M |
| 5 |
Genmab
GMAB
|
+$15.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.69% |
| 2 | Communication Services | 5.47% |
| 3 | Consumer Discretionary | 0.55% |
| 4 | Energy | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$425M
| $103M | 6.8% |
1,449,494
-478,335
| -25% | -$29.7M |
|
|
SPNE
2
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $98.5M | 6.49% |
6,263,260
+274,751
| +5% | +$4.7M |
|
|
MODN
3
DELISTED
MODEL N, INC.
MODN
| $83M | 5.47% |
2,478,532
+316,596
| +15% | +$10.7M |
|
|
4
Halozyme
HALO
$9.79B
| $60.1M | 3.96% |
1,477,496
-572,777
| -28% | -$23.9M |
|
|
XENT
5
DELISTED
Intersect ENT, Inc
XENT
| $58.1M | 3.83% |
2,136,823
-74,147
| -3% | -$1.83M |
|
6
Tandem Diabetes Care
TNDM
$1.34B
| $57.2M | 3.77% |
479,186
-49,420
| -9% | -$5.45M |
|
7
CareDx
CDNA
$2.26B
| $57.1M | 3.76% |
900,470
+4,213
| +0.5% | +$321K |
|
8
Omnicell
OMCL
$1.61B
| $52.5M | 3.46% |
354,042
-27,103
| -7% | -$4.15M |
|
9
NeoGenomics
NEO
$1.96B
| $50.9M | 3.36% |
1,055,960
-92,985
| -8% | -$4.3M |
|
10
AtriCure
ATRC
$1.92B
| $45M | 2.97% |
647,192
-125,583
| -16% | -$9.66M |
|
11
OptimizeRx
OPRX
$114M
| $43.4M | 2.86% |
507,384
-157,458
| -24% | -$9.88M |
|
12
Sutro Biopharma
STRO
$401M
| $41.4M | 2.73% |
219,144
+11,856
| +6% | +$2.25M |
|
|
13
Ultragenyx Pharmaceutical
RARE
$2.45B
| $39.8M | 2.62% |
441,159
+211,913
| +92% | +$19.2M |
|
14
Health Catalyst
HCAT
$154M
| $39.8M | 2.62% |
794,960
+5,567
| +0.7% | +$304K |
|
|
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $38.5M | 2.54% |
646,162
+29,038
| +5% | +$1.72M |
|
|
CUTR
16
DELISTED
Cutera, Inc.
CUTR
| $35.8M | 2.36% |
768,727
-248,796
| -24% | -$12.3M |
|
17
Axogen
AXGN
$2.27B
| $35.4M | 2.33% |
2,239,261
+17,588
| +0.8% | +$316K |
|
18
Insmed
INSM
$21.4B
| $33.8M | 2.23% |
1,227,283
-158,365
| -11% | -$4.15M |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $33.7M | 2.22% |
275,644
+864
| +0.3% | +$99.7K |
|
20
Krystal Biotech
KRYS
$10.1B
| $33.1M | 2.18% |
633,481
+106,831
| +20% | +$6.32M |
|
|
BCYC
21
Bicycle Therapeutics
BCYC
$269M
| $30.5M | 2.01% |
+732,731
| New | +$25.6M |
|
|
TPTX
22
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $30.1M | 1.98% |
452,878
+57,053
| +14% | +$4.06M |
|
23
Aldeyra Therapeutics
ALDX
$92.9M
| $26.2M | 1.73% |
2,985,712
-485,747
| -14% | -$4.46M |
|
|
24
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| $25.7M | 1.69% |
204,600
+121,931
| +147% | +$15.7M |
|
25
Teva Pharmaceuticals
TEVA
$40.8B
| $25.5M | 1.68% |
2,623,031
-350,061
| -12% | -$3.28M |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, First Light Asset Management held 86 positions worth $1.52B, down 8.9% from $1.67B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
First Light Asset Management withdrew a net $56.4M in Q3 2021, closing 3 positions and reducing 23 holdings. Its most notable exit was Arrowhead Research, an estimated $38.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, First Light Asset Management opened a new position in Bicycle Therapeutics worth $30.5M.
- First Light Asset Management's largest Q3 2021 buy was Bicycle Therapeutics: 732,731 shares worth $30.5M.
- First Light Asset Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $19.2M increase.
- First Light Asset Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $29.7M.
- First Light Asset Management fully exited Arrowhead Research in Q3 2021, selling an estimated $38.6M.
- First Light Asset Management's ten largest holdings make up 44% of its $1.52B portfolio in Q3 2021.
- First Light Asset Management opened 7 new positions and closed 3 in Q3 2021.
- First Light Asset Management's portfolio value fell 8.9% quarter-over-quarter to $1.52B.
Based on First Light Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.